CHICAGO, May 2, 2023
/PRNewswire/ -- Dimension Inx, a biomaterials platform company
developing therapeutics that restore tissue and organ function,
announced today the appointments of Paul K.
Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor.
Dr. Wotton fills the role of Independent Director of the Board,
created following Dimension's Series A raise of $15M completed in February
2023. He brings an expert perspective on platform growth
opportunities as a leader of multiple global biotechnology and
pharmaceutical companies. Dr. Wotton is a serial entrepreneur and
inventor with experience spanning scientific research, product
development, and transformational business transactions. Over his
35-year career, he has served as Chief Executive Officer of
Obsidian Therapeutics, Sigilon Therapeutics (NASDAQ:SGTX), Ocata
Therapeutics (NASDAQ:OCAT, acquired by Astellas), Antares Pharma
(NASDAQ:ATRS, acquired by Halozyme), and Topigen Pharmaceuticals.
He currently serves on the Boards of Combined Therapeutics,
Kytopen, Vericel Corporation (NASDAQ: VCEL), and Cynata
Therapeutics (ASX: CYP), and is a founder and Director of Avenge
Bio. He won the Ernst & Young Entrepreneur of the Year Regional
Life Sciences Award in 2014 for his work at Antares Pharma.
"We are thrilled to tap into Paul's unique expertise in
leveraging bioengineering platforms like ours," said Ramille Shah, Ph.D., Dimension Inx Co-Founder,
Head of R&D and Chief Scientific Officer. "Further, his
experiences as an entrepreneur and scaling innovative companies
will be instrumental as we navigate our therapeutic development
milestones ahead."
"I look forward to partnering with Dimension's outstanding team
and board as we embark on this important phase of growth," said Dr.
Wotton. "The company's proprietary biomaterials platform that uses
tissue-specific microenvironments can be a game changer for how we
direct cells to restore healthy tissues and organ systems to
deliver novel therapies to patients with high unmet
needs."
Chris Ehrlich joins the company
as Senior Advisor focusing on corporate development and financial
strategy. He is widely recognized for his strategic leadership
and ability to drive company growth, bringing over 25 years of
experience across biotech and medtech. Mr. Ehrlich currently serves
as the CEO of Phoenix Biotech Acquisition Corp. Previously, he was
the Senior Managing Director and Head of Locust Walk's biopharma
practice where he led multiple transactions for emerging life
sciences companies. Prior to Locust Walk, he was a Managing
Director at venture capital fund InterWest Partners, where he
served on the boards of KAI Pharmaceuticals (acquired by Amgen),
Biomimetic Therapeutics, Inc. (acquired by Wright Medical
Technologies), Invuity (acquired by Stryker), and Xenon
Pharmaceuticals.
"I am excited to work with the Dimension team and the board of
directors to realize the incredible potential of their
materials-centric approach to treating complex disease," said Mr.
Ehrlich. "The company has the passion, grit and talent to be a
strong partner in this new wave of engineered tissue
therapeutics."
Dimension Inx utilizes a proprietary biomaterials and
3D-printing platform to engineer three-dimensional
microenvironments that direct cell behavior and serve as
therapeutic interventions. The company announced the world's first
3D-printed regenerative product cleared by the U.S. FDA earlier
this year coincident with its Series A financing. This new funding
is directed at advancing development of therapeutics for functional
organ restoration, including restoring ovarian function to expand
options for fertility preservation.
"Our company is incredibly fortunate to benefit from the
corporate growth perspective that Paul and Chris bring to the
table," said Caralynn Nowinski
Collens, M.D., Co-Founder and Chief Executive Officer of
Dimension Inx. "Their partnership will undoubtedly prove valuable
as we augment our platform and continue to develop the next
generation of regenerative therapeutics to cure complex
disease."
For a full list of board directors and advisors, please visit
https://www.dimensioninx.com/about.
ABOUT DIMENSION INX
Dimension Inx is a biomaterials
platform company. We design and develop therapeutic products that
restore tissue and organ function.
Our materials-centric approach enables biofunctionality without
compromising manufacturability. We precisely tune our biomaterials
to create clinical solutions not otherwise possible. We work
shoulder-to-shoulder with biotech and medical device partners to
help solve their most challenging materials problems, and
internally develop medical products for various therapeutic
applications ranging from bone regeneration to fertility
preservation.
Dimension Inx is proudly based in Chicago, IL. To learn more about our team and
our technology, please visit www.dimensioninx.com.
Dimension Inx. Biomaterials, reimagined.
Media Contact
Cole
Johnson
Dimension Inx Corp.
ColeJohnson@dimensioninx.com
View original
content:https://www.prnewswire.com/news-releases/dimension-inx-announces-the-addition-of-biotech-industry-leaders-paul-k-wotton-phd-as-board-director-and-chris-ehrlich-as-senior-advisor-301813167.html
SOURCE Dimension Inx
